Karyopharm Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
60.56 M |
Public Float |
31.46 M |
Karyopharm Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.44 |
Market Cap |
$536.21 M |
Shares Outstanding |
60.86 M |
Public Float |
53.35 M |
Address |
85 Wells Avenue Newton Massachusetts 02459 United States |
Employees | - |
Website | http://www.karyopharm.com |
Updated | 07/08/2019 |
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. |